Abstract
The aim of this study was to assess the effect of systemic chemotherapy on the monoclonal protein levels of patients with solid tumors who also have a monoclonal gammopathy of undetermined significance (MGUS). All patients with solid tumors who were referred to our department for consideration of systemic chemotherapy were evaluated with serum protein electrophoresis (SPEP) for the presence of MGUS. When MGUS was confirmed with immunofixation, serial SPEP was performed during and after completion of chemotherapy. Over a 6-year period, 21 patients with solid tumors and MGUS were prospectively identified and assessed. At least 50% reduction of serum monoclonal protein was noted in 4 of 11 patients treated with paclitaxel or docetaxel with a platinum analogue and in 5 of 7 patients who received an irinotecan-containing regimen. Our data indicate that in MGUS patients treated with irinotecan-containing chemotherapy regimens, a high incidence of reduction in their monoclonal protein levels is observed. Since topotecan, another topoisomerase I inhibitor, has some activity in multiple myeloma, further evaluation of irinotecan may be warranted. Evaluation of larger numbers of MGUS patients treated with chemotherapy for their underlying malignancy may help identify “in vivo” potentially active agents and regimens for patients with overt myeloma.
Similar content being viewed by others
References
The International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–757
Hallen J (1966) Discrete gammaglobulin (M)-components in serum. Clinical study of 150 subjects without myelomatosis. Acta Med Scand 180:1
Migliore PJ, Alexanian R (1968) Monoclonal gammopathy in human neoplasia. Cancer 21:1127–1131
Talerman A, Haije WG (1973) The frequency of M-components in sera of patients with solid malignant neoplasms. Br J Cancer 27:276–282
Kelly R (1985) Benign monoclonal gammopathy: a reassessment of the problem. Immunol Invest 14:183–197
Gregersen H, Mellemkjaer L, Ibsen JS, Sorensen HT, Olsen JH, Pedersen JO, Dahlerhup JF (2000) Cancer risk in patients with monoclonal gammopathy of undetermined significance. Am J Hematol 63:1–6
Anagnostopoulos A, Evangelopoulou A, Sotou D, Gika D, Mitsibounas D, Dimopoulos MA (2002) Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece. Ann Hematol 81:357–361
Chen HP, Caroll JA (1980) Monoclonal gammopathy in carcinoma of the colon. Am J Clin Pathol 73:607–610
Dimopoulos MA, Arbuck S, Huber M, Weber D, Luckett R, Delasalle K, Alexanian R (1994) Primary therapy of multiple myeloma with paclitaxel (taxol). Ann Oncol 5:757–759
Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA (1998) Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). Am J Clin Oncol 21:553–556
Friedenberg WR, Graham D, Greipp P, Blood E, Winston RD (2003) The treatment of multiple myeloma with docetaxel (an ECOG study). Leuk Res 27:751–754
Burris HA, Fields SM (1994) Topoisomerase I inhibitors. Hematol Oncol Clin North Am 8:333–355
Kraut EH, Ju R, Muller M (1998) The use of topoisomerase I inhibitors in multiple myeloma. Semin Hematol 35 [Suppl 4]:32–38
Kraut EH, Crowley JJ, Wade JL, Laufman LR, Alsina M, Taylor SA, Salmon SE (1998) Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 16:589–592
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Anagnostopoulos, A., Galani, E., Gika, D. et al. Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. Ann Hematol 83, 658–660 (2004). https://doi.org/10.1007/s00277-004-0896-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-004-0896-1